Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways
Abstract Background The FLT3/ITD mutation exists in many acute myeloid leukemia (AML) patients and is related to the poor prognosis of patients. In this study, we attempted to evaluate the antitumor activity of simvastatin, a member of the statin class of drugs, in vitro and in vivo models of FLT3/I...
Saved in:
Main Authors: | Genhong Li (Author), Jingwei Yao (Author), Zhen Lu (Author), Lian Yu (Author), Qinwei Chen (Author), Lihong Ding (Author), Zhihong Fang (Author), Yin Li (Author), Bing Xu (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molecular characterisation of NPM1 and FLT3-ITD mutations in a central South African adult de novo acute myeloid leukaemia cohort
by: Jean F. Kloppers, et al.
Published: (2021) -
Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
by: Franziska Schmidt, et al.
Published: (2022) -
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML
by: Daelynn R. Buelow, et al.
Published: (2019) -
Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1
by: Li Liu, et al.
Published: (2024) -
The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease
by: Farhan Basit, et al.
Published: (2018)